[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-ischemic-stroke-from-large-vessel-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-ischemic-stroke-from-large-vessel-occlusion":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,74,103,129,155,176,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639101","hbo-after-thrombectomy-for-ais-with-lvo-100639101",false,"NCT07626450","HBO After Thrombectomy for AIS With LVO","HyperBaric Oxygen Therapy After ACute Thrombectomy in Acute Ischemic strOke Due to Large Vessel occlusioN","Inclusion Criteria:\n\n1. Age 18\\~80 years;\n2. Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines;\n3. The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours;\n4. Pre-stroke mRS score of 0 or 1;\n5. Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation;\n6. CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs;\n7. The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points;\n8. The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3;\n9. Patients or their family members sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with extensive bleeding or severe increase in infarct area, midline displacement (\\>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage;\n2. Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR\\>3.0 or APTT \\> 3 times normal or platelet count less than 50×10⁹\u002FL;\n3. Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST \\> 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr \\>1.5 times the upper limit of the normal range);\n4. Females of pregnancy, or positive pregnancy test prior to randomization;\n5. Severe persistent and medication-uncontrollable hypertension (systolic blood \\> 185 mmHg or diastolic blood \\> 110 mmHg)\n6. Baseline blood glucose of \\\u003C50 mg\u002FdL (2.78 mmol\u002FL) or \\>400 mg\u002FdL (22.20 mmol\u002FL);\n7. The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines \\> 3L\u002Fmin;\n8. End-stage disease other than the nervous system, life expectancy \\\u003C 90 days;\n9. Participating in other drug or medical device clinical trials;\n10. CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations;\n11. Patients with anemia, polycythemia or other conditions requiring urgent oxygen;\n12. Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active\u002Fchronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.).","ALL","18 Years","80 Years",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.",[27],"Acute Ischemic Stroke From Large Vessel Occlusion",[29,30,31,32],"Hyperbaric Oxygen Therapy","Thrombectomy","Acute ischemic stroke","Large vessel occlusion","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2027-10",{"name":43,"class":44},"Beijing Tiantan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100582063","phase-4-sglt2-inhibitor-utilization-re-perfusion-therapy-100582063","NCT06858436","SGLT2 Inhibitor Utilization Re-perfusion Therapy","The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial","SUPER","Inclusion Criteria:\n\n* Patients must have been diagnosed with acute ischemic stroke and large vessel occlusion by a neurologist, with confirmation supported by CT perfusion scans.\n* Patients must be scheduled to undergo mechanical thrombectomy.\n\nExclusion Criteria:\n\n* Patients with have stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73 m² on dialysis)\n* Patients with currently taking an SGLT2i or within 3 months prior to enrollment\n* Patients with a known hypersensitivity or allergic reaction to Canagliflozin\n* Patients with type 1 diabetes mellitus\n* Patients with pregnancy or lactation",{"count":55,"type":21},150,[57],"PHASE4","Background:\n\nReperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have demonstrated that Canagliflozin, an SGLT2 inhibitor, reduces astrocyte swelling and brain edema in a transient middle cerebral artery occlusion (tMCAo) model. While SGLT2 inhibitors have shown neuroprotective effects in the acute phase of ischemic stroke, their potential to mitigate hemorrhagic transformation and malignant edema following reperfusion therapy in humans remains unexamined.\n\nAims:\n\nThis study aims to evaluate the effect of SGLT2 inhibitors on hemorrhagic transformation and malignant edema in patients undergoing reperfusion therapy for acute ischemic stroke.\n\nMethods:\n\nThis is a multi-center, randomized, open-label, controlled study enrolling ischemic stroke patients aged 18 years or older who meet predefined inclusion and exclusion criteria. Participants will be randomized to receive Canagliflozin 100 mg once daily for 14 days or no additional treatment before undergoing mechanical thrombectomy. Clinical data collection will include baseline demographics, medical and medication history, NIHSS scores at admission and 24 hours post-reperfusion, stroke subtype, modified Thrombolysis in Cerebral Infarction (TICI) scores, laboratory results, and modified Rankin Scale (mRS) scores at discharge and 3 months post-stroke.\n\nThe primary outcome is to assess the association between Canagliflozin use and the severity of hemorrhagic transformation and malignant edema. Hemorrhagic transformation will be classified using the Heidelberg criteria, and malignant edema will be defined as a midline shift of ≥5 mm. Brain imaging, including CT scans at 24 hours post-intervention and additional scans as clinically indicated, will be reviewed by blinded radiologists. Brain MRA will also be performed to assess infarct size and edema progression.\n\nImportance:\n\nThis study aims to explore the potential for repurposing SGLT2 inhibitors as a therapeutic strategy in acute ischemic stroke. If Canagliflozin is shown to reduce hemorrhagic transformation and malignant edema, it could offer a novel adjunctive treatment to improve patient outcomes following reperfusion therapy.",[27],[61,62,63],"reperfusion therapy","SGLT2 inhibitor","malignant edema and transformation hemorrhage","NOT_YET_RECRUITING","2026-03-30",{"date":67,"type":37},"2026-04-03",{"date":69,"type":21},"2026-04-13",{"date":71,"type":21},"2027-10-31",{"name":73,"class":44},"Taichung Veterans General Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100621042","phase-2-efficacy-and-safety-of-intra-arterial-albumin-as-adjunct-to-mechanical-thrombectomy-in-acute-ischemic-stroke-100621042","NCT07365475","Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)","AMASS2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Acute anterior circulation large vessel occlusion (including ICA\u002FMCA-M1 tandem occlusion or isolated MCA-M1 occlusion) confirmed by CTA, MRA, or DSA, with successful recanalization (eTICI score ≥2b) confirmed by the final intraoperative DSA following mechanical thrombectomy\n* Baseline NIHSS scores ≥ 6\n* Non-contrast CT ASPECTS ≥6\n* Time from stroke onset (or last known well) to arterial puncture within 24 hours\n* Pre-stroke functional independence, defined as a modified Rankin Scale (mRS) score \\\u003C2\n* Written informed consent obtained from the patient or a legally authorized representative\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by cranial CT or MRI\n* Midline shift with significant mass effect on cranial CT or MRI\n* Isolated internal carotid artery (ICA) occlusion\n* History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension or pericardial effusion\n* Hemodynamically unstable arrhythmia (based on patient self-report or detected prior to infusion)\n* Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission\n* Acute or chronic renal failure (serum creatinine \\>2.0 mg\u002FdL\n* Severe anemia (hematocrit \\\u003C32%\n* Known hypersensitivity to albumin or blood products\n* Pregnancy\n* Persistent hypertension (blood pressure ≥180\u002F100mmHg) prior to albumin infusion\n* Current participation in other clinical trials\n* Life expectancy of less than 3 months\n* Concomitant severe pulmonary disease, such as chronic obstructive pulmonary disease, pulmonary fibrosis, pleural effusion, or acute respiratory distress syndrome\n* Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in the study",{"count":83,"type":21},306,[85],"PHASE2","Stroke remains a predominant global public health challenge, ranking as the third leading cause of death and the fourth leading contributor to disability-adjusted life years (DALYs). According to the Global Burden of Disease Study 2021, there are approximately 93.8 million prevalent stroke cases and 11.9 million new cases worldwide. China bears one of the heaviest burdens, with over 2 million new cases annually. Acute ischemic stroke (AIS), caused by acute cerebrovascular occlusion, accounts for 80% of all strokes. Approximately 30% of AIS cases result from large vessel occlusion (LVO), which typically carries a poor prognosis due to the extensive area of infarction . Research indicates that early recanalization significantly improves clinical outcomes. Currently, intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard treatments for achieving recanalization . For LVO-related AIS, MT has become the preferred clinical approach due to its extended therapeutic window and superior recanalization rates . However, despite successful recanalization in over 70% of patients, nearly 50% fail to achieve functional independence at 90 days, and mortality remains above 15% . Therefore, enhancing long-term functional outcomes in post-MT patients is a critical unmet clinical need. Human albumin is the most abundant protein in plasma. Beyond maintaining colloid osmotic pressure, it also possesses multiple biological effects, including anti-inflammatory, anti-platelet aggregation, antioxidant, and endothelial protective properties. We conducted a Phase I clinical trial (AMASS-1) for patients post-mechanical thrombectomy, administering human albumin via the internal carotid artery. The results showed that intra-arterial infusion of 20% human albumin at a dose of 0.60 g\u002Fkg was safe, with no significant differences in serious adverse reactions such as mortality \\[Albumin group (6.7%) vs Control group (6.7%), P \\> 0.05\\] and symptomatic intracranial hemorrhage \\[Albumin group (6.7%) vs Control group (13.3%), P \\> 0.05\\] compared to the control group. In summary, albumin adjunctive therapy demonstrates good safety and potential neuroprotective effects in patients after mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we plan to conduct a Phase II clinical trial of mechanical thrombectomy combined with intra-arterial albumin infusion for acute ischemic stroke. This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the efficacy and safety of intra-arterial infusion of 20% human serum albumin combined with mechanical thrombectomy versus mechanical thrombectomy alone in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who have achieved recanalization after mechanical thrombectomy. A total of 306 patients are planned to be enrolled and randomly assigned in a 1:1 ratio using a dynamic minimization method to two groups: the Albumin Group (0.6 g\u002Fkg 20% human serum albumin plus Mechanical Thrombectomy) and the Control Group (Mechanical Thrombectomy alone). The primary efficacy objective of this study is to evaluate whether immediate intra-arterial infusion of 20% human albumin (0.6 g\u002Fkg) via the internal carotid artery following successful recanalization (eTICI ≥2b) improves clinical outcomes in patients with acute anterior circulation large vessel occlusion stroke, compared with mechanical thrombectomy alone. The study also aims to evaluate the safety and feasibility of immediate intra-arterial infusion of 20% human albumin (0.6 g\u002Fkg) via the internal carotid artery in patients with acute anterior circulation large vessel occlusion stroke who have achieved successful recanalization (eTICI ≥2b) following standard mechanical thrombectomy.",[27],[89,90,91,92,93],"acute ischemic stroke","large vessel occlusion","mechanical thrombectomy","albumin","neuroprotection","2026-01-16",{"date":96,"type":37},"2026-01-26",{"date":98,"type":21},"2026-01-30",{"date":100,"type":21},"2028-08-30",{"name":102,"class":44},"Tianjin Huanhu Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100585634","phase-2-intra-arterial-tenecteplase-to-improve-the-microvascular-hemodynamics-after-mechanical-thrombectomy-100585634","NCT06904911","Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy","INTIMA-MT","Inclusion Criteria:\n\n* Patient\u002Flegally authorized representative has signed the Informed Consent Form\n* At least 18 years of age\n* Ability to comply with the study protocol, in the investigator's judgment\n* Acute ischemic stroke attributed to anterior circulation large vessel occlusion (of the internal carotid artery or first segment of the middle cerebral artery based on CTA, MRA, or catheter angiogram) being treated with mechanical thrombectomy\n* NIHSS ≥ 6 at the initiation of endovascular therapy (arterial puncture)\n* Time from stroke onset to IA-TNK administration \\\u003C 24 hours. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline\n* ASPECTS ≥ 6 on pre-MT CT imaging\n* If treated \\> 6 hours from stroke onset, CTP imaging must demonstrates favorable mismatch profile (based on RAPID processing: infarct core \\\u003C70 mL, mismatch ratio ≥ 1.8 and mismatch volume ≥ 15 mL)\n* Qualifying neuroimaging (CT and CTP, if applicable) must be obtained \\\u003C120 minutes prior to arterial puncture.\n\nExclusion Criteria:\n\n* Current participation in another investigational drug or device study\n* Known hypersensitivity or allergy to any ingredients of tenecteplase\n* Active internal bleeding\n* Known bleeding diathesis (Alzheimer's patients taking lecanemab)\n* Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \\> 1.7\n* Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)\n* Treatment with a thrombolytic within the last 3 months prior to randomization, inclusive of intravenous thrombolysis during the index stroke.\n* Baseline platelet count \\\u003C 100,000\u002Fmicroliter (results must be available prior to treatment)\n* Baseline blood glucose \\> 400 mg\u002FdL (22.20 mmol\u002FL)\n* Baseline blood glucose \\\u003C 50 mg\u002FdL needs to be normalized prior to randomization\n* Intracranial or intraspinal surgery or trauma within 2 months\n* Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months\n* History of acute ischemic stroke in the last 90 days\n* History of hemorrhagic stroke\n* Presumed septic embolus; suspicion of bacterial endocarditis\n* Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed\n* Pregnant\n* Systolic BP \\>185 mmHg or diastolic BP \\>110 mmHg, refractory to treatment\n* Suspicion of aortic dissection\n* Known allergy to iodine or iodinated contrast\n* Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram\n* Renal failure as defined by a serum creatinine \\> 3.0 mg\u002Fdl or GFR \\\u003C 30\n* Known intracranial neoplasm\n* GI bleeding within the past 21 days\n* Pre-existing medical or neurological disease that will confound the neurological or functional evaluations\n* Premorbid (prior to the index stroke) modified Rankin Scale (mRS) score ≥ 3\n\nAdditional neuroimaging exclusion criteria:\n\n* ASPECTS \\\u003C6 on pre-MT CT imaging\n* Acute intracranial hemorrhage or contrast extravasation on CT before or immediately after MT (prior to study drug administration)\n* Significant mass effect with midline shift on non-contrast CT before or immediately after MT\n* Cervical or intracranial stent placement during endovascular therapy\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA, MRA, or catheter angiography",{"count":111,"type":21},20,[85],"This is a prospective, single-arm, open-label study to evaluate the efficacy of intra-arterial tenecteplase in improving microvascular reperfusion following successful large vessel recanalization. Acute ischemic stroke patients with large anterior circulation large vessel occlusion will receive a single weight-based dose of intra-arterial tenecteplase after achieving successful large vessel recanalization (defined as TICI ≥ 2b) via standard of care mechanical thrombectomy. Microvascular flow will be assessed by quantitative angiography before and after the intra-arterial drug administration in order to quantify the impact of targeted thrombolysis on microvascular reperfusion. Reperfusion will be secondarily assessed with 24-hour imaging, final infarct volume will be quantified 72 hours following treatment, and functional outcome will be assessed in the short-term by the NIHSS and in the long-term by the 90-day modified Rankin Scale.",[27],[89,116,90,117,118,119],"ischemic stroke","reperfusion","adjuvant thrombolysis","intra-arterial thrombolysis","2026-01-07",{"date":122,"type":37},"2026-01-09",{"date":124,"type":37},"2025-12-11",{"date":126,"type":21},"2026-09-30",{"name":128,"class":44},"University of Pennsylvania",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":139,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":45},"100532271","prospective-registry-of-endovascular-thrombectomy-for-extra-large-ischemic-stroke-100532271","NCT06210633","Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke","XL STROKE: A Nationwide Prospective Registry of Endovascular Thrombectomy for Extra-large Ischemic Stroke With Large Vessel Occlusion","XL-STROKE","Inclusion Criteria:\n\nClinical inclusion criteria\n\n1. Age ≥18 years;\n2. Presenting with acute ischemic stroke within 24 hours of time from last known well;\n3. The patient or patient's representative signs a written informed consent form before enrollment.\n\nNeuroimaging inclusion criteria\n\n1. Occlusion of internal carotid artery, or the middle cerebral artery M1 or M2 segments confirmed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography;\n2. The baseline ASPECTS is 0 to 2 based on NCCT or diffusion weighted imaging, or cerebral extra-large ischemic core volume ≥85ml (defined as relative cerebral blood flow \\\u003C30% on CT perfusion or an apparent diffusion coefficient \\\u003C620×10\\^-6 mm2\u002Fs on MRI).\n\nExclusion criteria\n\n1. CT or MRI evidence of acute intracranial hemorrhage;\n2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;\n3. Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test;\n4. Previous bleeding disorders, severe heart, liver or kidney disease, or sepsis;\n5. Any terminal illness with life expectancy less than 6 months;\n6. Participation in other clinical treatment trials.",{"count":138,"type":21},1000,"3 Months","OBSERVATIONAL","Since 2015, many randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, five randomized controlled trials (ANGEL-ASPECT \\[Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core\\], LASTE \\[LArge Stroke Therapy Evaluation\\], RESCUE-Japan LIMIT \\[The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial\\], SELECT 2 \\[Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke\\], and TENSION \\[The Efficacy and Safety of Thrombectomy in Stroke with extended lesion and extended time window\\]) demonstrated the efficacy and safety of thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score \\[ASPECTS\\] ≥3 or infarct core \\\u003C100ml). Patients with extra-large infarct core (ASPECTS score of 2 or less) were excluded from these trials. Therefore, the efficacy of endovascular thrombectomy in patients with extra-large ischemic burden has not been well studied. The XL STROKE registry is aiming to investigate the clinical outcomes and safety of mechanical thrombectomy in acute extra-large ischemic stroke.",[143,27],"Acute Ischemic Stroke (AIS)",[31,90,145],"endovascular thrombectomy","2025-12-24",{"date":148,"type":37},"2025-12-31",{"date":150,"type":37},"2024-01-20",{"date":152,"type":21},"2026-03-31",{"name":154,"class":44},"Zhongming Qiu",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100615575","phase-2-the-preliminary-efficacy-and-safety-of-intra-arterial-albumin-as-adjunct-to-mechanical-thrombectomy-in-acute-ischemic-stroke-100615575","NCT07294391","The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke","The Preliminary Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke：Dual-Center, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* 1.Age ≥ 18 years; 2.ICA or MCA-M1 occlusion, confirmed by preoperative CTA\u002FMRA\u002FDSA. ICA occlusion can be cervical or intracranial, with or without tandem MCA lesions; Treated with EVT resulting in recanalization ((expanded Thrombolysis in Cerebral Infarction \\[eTICI\\] 2b-3); 3.Baseline NIHSS scores ≥ 6; 4.Baseline ASPECTS ≥6 on non-contrast CT; 5.The time from stroke onset\u002Flast seen well to arterial puncture is within 24 hours; 6.No significant pre-stroke disability (pre-stroke mRS ≤2); 7.Signed informed consent from the patient or the legally authorized representative\n\nExclusion Criteria:\n\n* 1.Presence of intracranial hemorrhage on head CT or MRI； 2.Midline shift with significant mass effect on head CT or MRI； 3.History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension, pericardial effusion, etc； 4.Arrhythmia accompanied by hemodynamic instability； 5.Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission； 6.Acute or chronic renal failure (serum creatinine \\>2.0 mg\u002FdL)； 7.Severe anemia (hematocrit \\\u003C32%)； 8.Known allergy to albumin or blood products； 9.Pregnant women； 10.Persistent blood pressure ≥180\u002F100 mmHg prior to albumin infusion； 11.Concurrent participation in another clinical trial； 12.Life expectancy of less than 3 months； 13.Coexisting severe pulmonary diseases such as Chronic Obstructive Pulmonary Disease, pulmonary fibrosis, pleural effusion, pulmonary hypertension, or acute respiratory distress syndrome； 14.Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this study.",{"count":163,"type":21},60,[85],"Albumin-assisted therapy has demonstrated good safety and potential neuroprotective effects following mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we are conducting a Phase IIa clinical trial of intra-arterial albumin administration combined with mechanical thrombectomy in patients with acute ischemic stroke. This is a double-center, prospective, open-label, endpoint-blinded, randomized controlled trial designed to preliminarily assess the efficacy and safety of intra-arterial infusion of 20% human albumin after successful recanalization in patients with acute ischemic stroke caused by anterior circulation large-vessel occlusion who undergo mechanical thrombectomy. A total of 60 patients will be enrolled and randomized in a 1:1 ratio by dynamic minimization into two groups: the albumin group (0.6 g\u002Fkg of 20% human albumin solution plus mechanical thrombectomy) and the control group (mechanical thrombectomy alone).\n\nThe primary objective of this study is to preliminarily evaluate whether intra-arterial infusion of 0.6 g\u002Fkg of 20% human albumin via the internal carotid artery immediately after achieving successful recanalization (eTICI ≥ 2b) can reduce infarct volume compared with mechanical thrombectomy alone in patients with anterior circulation large-vessel occlusion who undergo standard mechanical thrombectomy. The secondary objective is to assess the safety and feasibility of intra-arterial infusion of 0.6 g\u002Fkg of 20% human albumin immediately after successful recanalization in this patient population.",[27],[31,90,91,92,93],"2025-12-07",{"date":170,"type":37},"2025-12-19",{"date":172,"type":21},"2025-12-10",{"date":174,"type":21},"2026-12-01",{"name":102,"class":44},{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":205},"100544538","safety-and-effectiveness-of-mechanical-thrombectomy-using-the-anaconda-ana-funnel-catheter-100544538","NCT06370182","Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter","A Prospective, Randomized, Dual-arm Multi-center Study to Assess the Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter in Combination With a Stent Retriever","ATHENA","Key Inclusion Criteria:\n\nSubjects meeting all inclusion criteria will be considered for enrollment in the study.\n\n1. Age 22 to 85 years.\n2. Informed consent was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative).\n3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.\n4. Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points.\n5. Pre-ictal mRS score of 0,1 or 2.\n6. Treatable within 16 hours of symptom onset, defined as point in time when the subject was last observed to be asymptomatic; treatment start is defined by arterial puncture time.\n7. If indicated, thrombolytic therapy shall be initiated per the institution's usual care and the most recent version of the AHA\u002FASA Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.\n8. Occlusion (eTICI ≤ 1 flow) of the terminal carotid artery, middle cerebral artery M1 segment or, dominant or proximal M2 segment, indicated for mechanical thrombectomy, confirmed with conventional angiography or CTA\u002FMRA.\n9. Imaging criteria:\n\n   * Perfusion weighted criterion: volume of diffusion restriction visually assessed\n\n     ≤ 50 mL on CTP\u002FMRP, or\n   * CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT\u002FDWI-MRI. (Inclusion of subjects with ASPECTS 5 is permitted at centers performing scoring on MRI)\n10. The subject is indicated for a neurovascular thrombectomy procedure with an approved stent retriever per its Instructions for Use.\n\nKey Exclusion Criteria:\n\nSubjects who meet any of the exclusion criteria will be ineligible for participation in the study.\n\nThe following exclusion criteria will be assessed pre-operatively:\n\n1. Subject was diagnosed with a stroke in the past year.\n2. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.\n3. Known hemorrhagic diathesis, coagulation factor deficiency, oral anticoagulant therapy with antivitamin K, with INR \\>3.0, or thrombocytopenia - baseline platelet count \\\u003C 50,000 platelets\u002FmL.\n4. Known baseline glucose of \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL.\n5. Severe, sustained uncontrolled hypertension refractory to treatment (systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg).\n6. Serious, advanced, or terminal disease with anticipated life expectancy of less than 1 year.\n7. Known cancer with metastases.\n8. History of life-threatening allergy (more than rash) to contrast medium.\n9. Known renal insufficiency with creatinine ≥3 mg\u002FdL or glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin.\n10. Subject is a current user or has a recent history of cocaine \\&\u002For heroin use.\n11. Known pregnancy and\u002For lactating female.\n12. Subject is participating in a concurrent study involving an investigational drug or device that would impact the primary endpoint of this study.\n13. Subject is unlikely to be available for a 90-day follow-up (e.g. no fixed home address, visitor from overseas, etc.)\n14. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).\n15. Significant mass effect with midline shift.\n16. Evidence of intracranial tumor (except asymptomatic meningioma of ≤ 2cm in diameter).\n17. Suspicion of aortic dissection, presumed septic embolus, or suspicion of bacterial endocarditis.\n18. History of preexisting stent proximal to or at the occlusion site that may preclude safe deployment or recovery of the stent retriever.\n19. Vessel tortuosity too difficult to allow endovascular access of the intracranial ICA per investigator judgement. Indicators of vessel tortuosity include but are not limited to the presence of carotid loops and type 3 aortic arches.","22 Years","85 Years",{"count":187,"type":21},327,[24],"The objective of this study is to assess the safety and effectiveness of mechanical thrombectomy (MT) using the ANA funnel catheter in its intended use, which is to facilitate the navigation and deployment of other neurovascular devices and to allow flow arrest during mechanical thrombectomy procedures performed in subjects experiencing acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO) and treated within 24 hours of symptom onset.",[27],[192,193,194,195,91],"flow arrest","flow restriction","funnel","guide catheter","2025-12-05",{"date":124,"type":37},{"date":199,"type":37},"2024-09-09",{"date":201,"type":21},"2027-12",{"name":203,"class":204},"Anaconda Biomed S.L.","INDUSTRY",22,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":214,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":45},"100596210","efficacy-and-safety-of-plasma-adsorption-combined-with-evt-for-ais-lvo-100596210","NCT07042490","Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO","Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial","PROMOTE-EVT","Inclusion Criteria:\n\n1. Age 18-80 years, male or female.\n2. Diagnosis of acute ischemic stroke within 12 hours of symptom onset, underwent endovascular thrombectomy (EVT) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by DSA as ICA,MCA-M1,MCA-M2,ACA-A1,ACA-A2 occlusion or tandem lesion) and achieve successful recanalization (mTICI grade 2b\u002F3).\n3. Baseline NIHSS after EVT ≥ 6 and ≤25 points.\n4. Randomization and the first plasma adsorption can be initiated within 12 hours after EVT.\n5. Pre-stroke mRS≤ 2 points.\n6. Patient\u002Flegally family members have signed the Informed consent form.\n\nExclusion Criteria:\n\n1. Imaging after EVT indicated malignant brain edema with midline shift or brain herniation and surgical treatment was planned.\n2. Parenchymal hemorrhage type 1, or type 2 confirmed by CT.\n3. Allergic to any ingredient of the plasma separator, the adsorption device, or the piping.\n4. Contraindications to plasma adsorption, platelet count \\\u003C60×10\\^9\u002FL,white blood cell\\\u003C4×10\\^9\u002FL, uncontrolled hypertension with persistent systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg, uncontrolled hypotension, systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg.\n5. Previous history of malignant tumors, autoimmune diseases or being treated with immunosuppressants, hormones, or tumor necrosis factor inhibitors.\n6. Previous history of organic heart disease and NYHA Class III or IV.\n7. Currently taking anticoagulant(dabigatran, rivaroxiban, warfarin, etc.), previous history of serious hematological system disorders, or abnormal coagulation function (international normalized ratio \\[INR\\], activated partial thromboplastin time \\[APTT\\], prothrombin time \\[PT\\] upper limit of the normal range).\n8. Severe liver and kidney dysfunction or abnormal laboratory test results（serum aspartate aminotransferase or alanine aminotransferase \\>3 times the upper limit of normal, serum creatinine\\>265umol\u002Fl(\\>3mg\u002Fdl)）.\n9. Pregnancy , lactation or life expectancy of less than 3 months or inability to complete the study for other reasons.\n10. Unwilling to be followed up or poor compliance.\n11. Current or past participation in other clinical research, or participation in this study within 3 months prior to admission.\n12. Other conditions that the researchers think make the patient unsuitable for the study.",{"count":215,"type":21},100,[24],"The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.",[27,219],"Endovascular Thrombectomy",[31,221,219],"Plasma adsorption","2025-06-27",{"date":224,"type":37},"2025-06-29",{"date":226,"type":21},"2025-06-30",{"date":228,"type":21},"2027-06-30",{"name":230,"class":44},"Yi Yang"]